药物防治胆囊结石研究进展

徐敬昌; 叶辉; 王大松

doi:10.3969/j.issn.1001-5256.2018.11.041

药物防治胆囊结石研究进展

DOI: 10.3969/j.issn.1001-5256.2018.11.041

四川大学华西医院胆道外科

基金项目:

公益性行业科研专项(201502014)；

详细信息

中图分类号: R575.62
计量
- 文章访问数: 2196
- HTML全文浏览量: 74
- PDF下载量: 442
- 被引次数: 0
出版历程
- 出版日期: 2018-11-20

Research advances in drugs for the prevention and treatment of gallstones

Research funding:

摘要

摘要: 胆囊结石的治疗以手术、内镜治疗为主,近年大量研究提出了药物防治胆囊结石的新观点、新思路。总结了目前已进入临床研究的胆汁酸类药物、他汀类药物、依泽替米贝以及作用于胆固醇和胆汁酸稳态相关特定核受体的药物在防治胆囊结石中的效用和安全性,并指出可能具有胆囊结石防治意义的药物、分子位点,为个体化胆囊结石药物防治策略制订和研究提供依据。
- 胆囊结石病 /
- 药物疗法 /
- 综述
Abstract: The treatment of gallstones mainly relies on surgery and endoscopy, and in recent years, a large number of studies have proposed new ideas and thoughts for drugs in the prevention and treatment of gallstones. This article summarizes the efficacy and safety of bile acid drugs, statins, ezetimibe, and drugs acting on specific nuclear receptors involved in cholesterol and bile acid homeostasis, which have entered the clinical trial stage, in preventing and treating gallstones. It is pointed out that certain drugs and molecular sites may have some clinical effects in the prevention and treatment of gallstones, which provides a basis for developing individualized strategies for the prevention and treatment of gallstones with drugs.
- cholecystolithiasis /
- drug therapy /
- review

HTML全文

参考文献(55)

[1]FARTHING M, ROBERTS SE, SAMUEL DG, et al.Survey of digestive health across Europe:Final report.Part 1:The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe[J].United European Gastroenterol J, 2014, 2 (6) :539-543.

[2]SPANIER BW, DIJKGRAAF MG, BRUNO MJ.Epidemiology, aetiology and outcome of acute and chronic pancreatitis:An update[J].Best Pract Res Clin Gastroenterol, 2008, 22 (1) :45-63.

[3]ZHU XG, ZHANG SD, HUANG ZQ.The trend of the gallstone disease in China over thepast decade[J].Chin J Surg, 1995, 33 (11) :652-658. (in Chinese) 祝学光, 张圣道, 黄志强.我国胆石病十年来的变迁[J].中华外科杂志, 1995, 33 (11) :652-658.

[4]FESTI D, REGGIANI ML, ATTILI AF, et al.Natural history of gallstone disease:Expectant management or active treatment?Results from a population-based cohort study[J].J Gastroenterol Hepatol, 2010, 25 (4) :719-724.

[5]DIEHL AK.Epidemiology and natural history of gallstone disease[J].Gastroenterol Clin North Am, 1991, 20 (1) :1-19.

[6] CHEN Y, KONG J, WU S.Cholesterol gallstone disease:Focusing on the role of gallbladder[J].Lab Invest, 2015, 95 (2) :124-131.

[7]CHUANG SC, HSI E, LEE KT.Mucin genes in gallstone disease[J].Clinica Chimica Acta, 2012, 413 (19) :1466-1471.

[8]HOUSSET C, CHRETIEN Y, DEBRAY D, et al.Functions of the gallbladder[J].Compr Physiol, 2016, 6 (3) :1549-1577.

[9]LAVOIE B, NAUSCH B, ZANE E A, et al.Disruption of gallbladder smooth muscle function is an early feature in the development of cholesterol gallstone disease[J].Neurogastroenterol Motil, 2012, 24 (7) :e313-e324.

[10]di CIAULA A, WANG DQ, GARRUTI G, et al.Therapeutic reflections in cholesterol homeostasis and gallstone disease:A review[J].Curr Med Chem, 2014, 21 (12) :1435-1447.

[11]LI Q, GE X, XU X, et al.Comparison of the gene expression profiles between gallstones and gallbladder polyps[J].Int J Clin Exp Pathol, 2014, 7 (11) :8016-8023.

[12]DANZINGER RG, HOFMANN AF, SCHOENFIELD LJ, et al.Dissolution of cholesterol gallstones by chenodeoxycholic acid[J].N Engl J Med, 1972, 286 (1) :1-8.

[13]RADCHENKO VG, SELIVERSTOV PV, SITKIN SI.New aspects of pharmacological effects of ursodeoxycholic acid[J].Eksp Klin Gastroenterol, 2014, 8:4-10.

[14]MAY GR, SUTHERLAND LR, SHAFFER EA.Efficacy of bile acid therapy for gallstone dissolution:A meta-analysis of randomized trials[J].Aliment Pharmacol Ther, 1993, 7 (2) :139-148.

[15]LEE JM, HYUN JJ, CHOI IY, et al.Comparison on response and dissolution rates between ursodeoxycholic acid alone or in combination with chenodeoxycholic acid for gallstone dissolution according to stone density on CT scan:Strobe compliant observation study[J].Medicine (Baltimore) , 2015, 94 (50) :e2037.

[16]VENNEMAN NG, van ERPECUM KJ.Gallstone disease:Primary and secondary prevention[J].Best Pract Res Clin Gastroenterol, 2006, 20 (6) :1063-1073.

[17]CARRILHO-RIBEIRO L, PINTO-CORREIA A, VELOSA J, et al.A ten-year prospective study on gallbladder stone recurrence after successful extracorporeal shock-wave lithotripsy[J].Scand JGastroenterol, 2006, 41 (3) :338-342.

[18]GURUSAMY KS, DAVIDSON BR.Gallstones[J].BMJ, 2014, 348:g2669.

[19]QUESADA BM, KOHAN G, ROFF HE, et al.Management of gallstones and gallbladder disease in patients undergoing gastric bypass[J].World J Gastroenterol, 2010, 16 (17) :2075-2079.

[20]ADAMS LB, CHANG C, POPE J, et al.Randomized, prospective comparison of ursodeoxycholic acid for the prevention of gallstones after sleeve gastrectomy[J].Obes Surg, 2016, 26 (5) :990-994.

[21]COUPAYE M, CALABRESE D, SAMI O, et al.Evaluation of incidence of cholelithiasis after bariatric surgery in subjects treated or not treated with ursodeoxycholic acid[J].Surg Obes Relat Dis, 2017, 13 (4) :681-685.

[22]BOERLAGE TCC, HAAL S, de BRAUW LM, et al.Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery:Study protocol for a randomized controlled trial (UPGRADE trial) [J].BMC Gastroenterol, 2017, 17 (1) :164.

[23]KHARITONOVA LA, ERMOLENKO NS.The treatment of gallbladder cholesterosis in children[J].Eksp Klin Gastroenterol, 2014, 1:42-45.

[24]TOMIDA S, ABEI M, YAMAGUCHI T, et al.Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones:A cohort analysis[J].Hepatology, 1999, 30 (1) :6-13.

[25]HYUN JJ, LEE HS, KIM CD, et al.Efficacy of magnesium trihydrate of ursodeoxycholic acid and chenodeoxycholic acid for gallstone dissolution:A prospective multicenter trial[J].Gut Liver, 2015, 9 (4) :547-555.

[26]WANG DQ.Regulation of intestinal cholesterol absorption[J].Annu Rev Physiol, 2007, 69:221-248.

[27]WANG DQ, ZHANG L, WANG HH.High cholesterol absorption efficiency and rapid biliary secretion of chylomicron remnant cholesterol enhance cholelithogenesis in gallstone-susceptible mice[J].Biochim Biophys Acta, 2005, 1733 (1) :90-99.

[28]LAURIDSEN BK, STENDER S, FRIKKE-SCHMIDT R, et al.Genetic variation in the cholesterol transporter NPC1L1, ischaemic vascular disease, and gallstone disease[J].Eur Heart J, 2015, 36 (25) :1601-1608.

[29]WANG HH, PORTINCASA P, MENDEZ-SANCHEZ N, et al.Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones[J].Gastroenterology, 2008, 134 (7) :2101-2110.

[30]BODMER M, BRAUCHLI YB, KRAHENBUHL S, et al.Statin use and risk of gallstone disease followed by cholecystectomy[J].JAMA, 2009, 302 (18) :2001-2007.

[31]TSAI CJ, LEITZMANN MF, WILLETT WC, et al.Statin use and the risk of cholecystectomy in women[J].Gastroenterology, 2009, 136 (5) :1593-1600.

[32]ERICHSEN R, FROSLEV T, LASH TL, et al.Long-term statin use and the risk of gallstone disease:A population-based case-control study[J].Am J Epidemiol, 2011, 173 (2) :162-170.

[33]MARTIN D, SCHMIDT R, MORTENSEN EM, et al.Association of statin therapy and risks of cholelithiasis, biliary tract diseases, and gallbladder procedures:Retrospective cohort analysis of a USpopulation[J].Ann Pharmacother, 2016, 50 (3) :161-171.

[34]CHIU HF, CHEN CC, KUO HW, et al.Statin use and the risk of gallstone disease:A population-based case-control study[J].Expert Opin Drug Saf, 2012, 11 (3) :369-374.

[35]SUURONEN S, NISKANEN L, PAAJANEN P, et al.Declining cholecystectomy rate during the era of statin use in Finland:A population-based cohort study between 1995 and 2009[J].Scand JSurg, 2013, 102 (3) :158-163.

[36]PULKKINEN J, ESKELINEN M, KIVINIEMI V, et al.Effect of statin use on outcome of symptomatic cholelithiasis:A case-control study[J].BMC Gastroenterol, 2014, 14:119.

[37]JAIN MK, RIDKER PM.Anti-inflammatory effects of statins:Clinical evidence and basic mechanisms[J].Nat Rev Drug Discov, 2005, 4 (12) :977-987.

[38]YU XH, QIAN K, JIANG N, et al.ABCG5/ABCG8 in cholesterol excretion and atherosclerosis[J].Clin Chim Acta, 2014, 428:82-88.

[39]LIU Y, BINZ J, NUMERICK MJ, et al.Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra-and extrahepatic cholestasis[J].J Clin Invest, 2003, 112 (11) :1678-1687.

[40]MODICA S, PETRUZZELLI M, BELLAFANTE E, et al.Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis[J].Gastroenterology, 2012, 142 (2) :355-65.e1-e4.

[41]MOSCHETTA A, BOOKOUT AL, MANGELSDORF DJ.Prevention of cholesterol gallstone disease by FXR agonists in a mouse model[J].Nat Med, 2004, 10 (12) :1352-1358.

[42]LEE FY, de AGUIAR VALLIM TQ, CHONG HK, et al.Activation of the farnesoid X receptor provides protection against acetaminophen-induced hepatic toxicity[J].Mol Endocrinol, 2010, 24 (8) :1626-1636.

[43]ZHANG Y, LEE FY, BARRERA G, et al.Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice[J].Proc Natl Acad Sci U S A, 2006, 103 (4) :1006-1011.

[44]KIM I, MORIMURA K, SHAH Y, et al.Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice[J].Carcinogenesis, 2007, 28 (5) :940-946.

[45]MARAN RRM, THOMAS A, ROTH M, et al.Farnesoid X receptor deficiency in mice leads to increased intestinal[J].J Pharmacol Exp Ther, 2009, 328 (2) :469-477.

[46]CARIELLO M, PICCININ E, GARCIA-IRIGOYEN O, et al.Nuclear receptor FXR, bile acids and liver damage:Introducing the progressive familial intrahepatic cholestasis with FXR mutations[J].Biochim Biophys Acta, 2018, 1864 (4 Pt B) :1308-1318.

[47]CHENG Q, INABA Y, LU P, et al.Chronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity[J].Mol Endocrinol, 2015, 29 (4) :571-582.

[48]FENG J, CUI NQ.Current status and perspectives of integrated traditional Chinese and Western medicine therapy for cholelithiasis[J].JClin Hepatol, 2018, 34 (4) :704-709. (in Chinese) 冯健, 崔乃强.中西医结合治疗胆石病的现状与展望[J].临床肝胆病杂志, 2018, 34 (4) :704-709.

[49]XU GQ, XU CF, CHEN HT, et al.Association of caveolin-3 and cholecystokinin A receptor with cholesterol gallstone disease in mice[J].World J Gastroenterol, 2014, 20 (28) :9513-9518.

[50]WANG HH, LIU M, PORTINCASA P, et al.Lack of endogenous cholecystokinin promotes cholelithogenesis in mice[J].Neurogastroenterol Motil, 2016, 28 (3) :364-375.

[51]HOLAN KR, HOLZBACH RT, HERMANN RE, et al.Nucleation time:A key factor in the pathogenesis of cholesterol gallstone disease[J].Gastroenterology, 1979, 77 (4 Pt 1) :611-617.

[52]CHUANG SC, HSI E, WANG SN, et al.Polymorphism at the mucin-like protocadherin gene influences susceptibility to gallstone disease[J].Clin Chim Acta, 2011, 412 (23-24) :2089-2093.

[53]HO SB, SHEKELS LL, TORIBARA NW, et al.Altered mucin core peptide expression in acute and chronic cholecystitis[J].Dig Dis Sci, 2000, 45 (6) :1061-1071.

[54]ZEN Y, HARADA K, SASAKI M, et al.Lipopolysaccharide induces overexpression of MUC2 and MUC5AC in cultured biliary epithelial cells:Possible key phenomenon of hepatolithiasis[J].Am JPathol, 2002, 161 (4) :1475-1484.

[55]WANG HH, AFDHAL NH, GENDLER SJ, et al.Targeted disruption of the murine mucin gene 1 decreases susceptibility to cholesterol gallstone formation[J].J Lipid Res, 2004, 45 (3) :438-447.

施引文献

资源附件(0)

访问统计